RecruitingNot applicableNCT07119970
Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)
Studying Myeloproliferative neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Bordeaux
- Principal Investigator
- Alexandre GUYalexandre.guy@chu-bordeaux.fr
- Intervention
- Additional blood sampling(biological)
- Enrollment
- 300 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (15)
- CHU d'Angers, Service des maladies du Sang, Angers, France
- CH de la Côte Basque, Service Hématologie, Bayonne, France
- CHU de Bordeaux, Service Hématologie Biologique, Bordeaux, France
- CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire, Bordeaux, France
- CHU de Brest, Service Hématologie et Hémostase Clinique, Brest, France
- APHP-Hôpital Mondor, Service Hématologie Clinique et Thérapie Cellulaire, Créteil, France
- CHD de Vendée, Service Onco-hématologie, La Roche-sur-Yon, France
- APHP-Hôpital Bicêtre, Service Hématologie Clinique Ambulatoire, Le Kremlin-Bicêtre, France
- CH de Libourne, Service Hématologie, Libourne, France
- CHU de Limoges, Service Hématologie Clinique et de Thérapie Cellulaire, Limoges, France
- CH des Pays de Morlaix, Service Onco-Hématologie, Morlaix, France
- CHU de Nantes, Service Hématologie Clinique, Nantes, France
- Hôpital Privé du Confluent, Service Hématologie, Nantes, France
- APHO-Hôpital Saint-Louis, Centre d'Investigations Cliniques, Paris, France
- CH de Roubaix, Service Hématologie, Roubaix, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07119970 on ClinicalTrials.govOther trials for Myeloproliferative neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07441694Study of INCA036978 in Participants With Myeloproliferative NeoplasmsIncyte Corporation
- RECRUITINGPHASE2NCT07148947Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsUniversity of Washington
- RECRUITINGPHASE2NCT07228624Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesFred Hutchinson Cancer Center
- RECRUITINGPHASE2NCT06661915A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)National Cancer Institute (NCI)
- RECRUITINGPHASE3NCT06468033P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskPharmaEssentia
- RECRUITINGNANCT05745285Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and CareUniversity of Miami
- RECRUITINGNCT06480591Evaluation of the Pathobiology of CALR-mutated MPN CellsWake Forest University Health Sciences
- RECRUITINGPHASE3NCT06740916Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients with Aspirin ResistanceSiriraj Hospital